Please provide your email address to receive an email when new articles are posted on . Patients treated with PCSK9 inhibitors had reduced risk for venous thromboembolism, especially if they had ...

Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C compared to placebo in Phase 3 trials RAHWAY, N.J.--(BUSINESS WIRE)- ...

Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of 2025 Dosing in the Heart-2 trial has moved to the 0.6 mg/kg cohort VERVE-301 nominated ...

SHANGHAI and SANTA BARBARA, Calif., Dec. 17, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in next-generation RNAi medicines, today announced the submission of RN5681 to the Australian Human ...

Among people with a previous heart attack or stroke, or who are at high risk for one, a daily oral medication may offer an effective alternative to injections of PCSK9 inhibitors to lower low-density ...

Deepak L. Bhatt, MD, MPH: Speaking of PCSK9 inhibitors, let’s turn back to Dr Budoff. I was going to say this is a new class of medicine. They’re not that new anymore but are still exciting. Can you ...

Over the past several days, two major developments have emerged in the world of cholesterol-lowering therapies—specifically concerning the heavy-hitters known as PCSK9 inhibitors. In this letter, I’d ...

A new case-control genetic study is reassuring in finding no association between a genetic proxy for pharmacologic PCSK9 inhibition and either heart failure or adverse cardiac remodeling in a large ...

PCSK9 inhibitors are a type of medication that lowers cholesterol. Doctors may prescribe them to people alongside statins and other cholesterol-lowering drugs. Doctors commonly prescribe statins to ...

Lerodalcibep-liga, a once-monthly PCSK9 inhibitor, significantly reduces LDL-C in hypercholesterolemia, including HeFH, with FDA approval for subcutaneous use. The LIBerate Program showed sustained ...